Glenmark Life Sciences IPO sails through within 90 minutes

Most analysts are positive on the company’s future prospects and suggest subscribing to the issue. They believe the company, which is a spin off of Glenmark Pharma, is well placed in the Active Pharmaceutical Ingredient (API) business.

Original source: https://health.economictimes.indiatimes.com/news/pharma/84787678?utm_source=RSS&utm_medium=ETRSS

Related Posts